Gen-Probe Shareholder Aims To Block $3.7B Hologic Deal
In a Delaware Chancery Court complaint, shareholder Timothy Coyne alleged that Gen-Probe’s directors breached their duty to investors by signing off on the $82.75-per-share deal. He said the buyout comes during a lull in the San Diego-based company’s stock price that does not reflect its recent success and potential for growth.
In fact, the deal was...
Already a subscriber? Click here to login